Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

New Corporate Presentation and Investor Factsheet

24th Apr 2025 07:00

RNS Number : 9448F
Aptamer Group PLC
24 April 2025
 

 

24 April 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

New Corporate Presentation and Investor Factsheet

 

Aptamer Group plc (AIM: APTA), the leading developer of next generation synthetic binders delivering innovation to the life science industry, is pleased to announce that it has published a new corporate presentation and investor factsheet. These materials are now available on the investor relations section of the Group's website (https://aptamergroup.com/investors/reports-and-presentations/).

 

The corporate presentation outlines Aptamer's strategy, operational progress and financial performance, offering a comprehensive overview of the Group's growth potential. Complementing this, the investor factsheet provides a succinct two-page summary, focused on highlighting key operational and financial metrics to support investors in their evaluation of the Group.

 

No new material information has been disclosed in either of these publications.

 

- Ends -

For further information, please contact: 

 

Aptamer Group plc

Dr Arron Tolley, Chief Executive Officer

+44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Jade Bayat

+44 (0) 20 3368 3550

Turner Pope Investments (TPI) Limited - Broker

James Pope / Andrew Thacker

+44 (0) 20 3657 0050

Northstar Communications Limited - Investor Relations

Sarah Hollins 

+44 (0) 113 730 3896

 

About Aptamer Group

Aptamer Group is a leading developer of next generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.

Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.

To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABCGDSRXDDGUX

Related Shares:

Aptamer Group
FTSE 100 Latest
Value8,554.80
Change23.19